Pancreatic cancer research explores early detection and prevention


A study monitoring people at high risk has found cancers at early stages. Separate mouse experiments test treatment of precancerous growths, but neither approach has established a survival benefit in people.
Researchers are exploring two complementary ways to tackle pancreatic cancer: monitor people at high risk to find disease earlier, and treat abnormal growths before they become cancerous. An ongoing human study is testing the first approach; experiments in mice offer evidence for the second, according to Nature’s October 1 report.
The second approach is called cancer interception: treating abnormally growing tissue to stop it from becoming cancerous and spreading. The reason to act earlier is concrete. More than half of pancreatic cancers are diagnosed only after the disease has spread to other organs. Symptoms can be vague, and pancreatic tumours can grow around major blood vessels, making them difficult to remove.
PRECEDE is a clinical study for people with a family history of pancreatic cancer, certain abnormal growths on the pancreas, or a genetic profile that increases their risk. Diane Simeone, director of the Moores Cancer Center at University of California San Diego Health, and her colleagues launched it to determine whether frequent monitoring improves survival—and, if so, by how much.
| Measure | Planned or reported number |
|---|---|
| Enrollment target | 20,000 people |
| Enrolled, as reported by Simeone at September’s American Association for Cancer Research conference | A little more than 12,000 people |
| Participants diagnosed with pancreatic cancer |

Researchers compared women’s survey responses with electronic medical records, finding gaps in information about menopause status, timing and symptoms.
Finding cancers early does not by itself establish that monitoring extends life. Whether PRECEDE’s monitoring improves survival remains unresolved.
The team also plans to use participants’ samples to evaluate experimental blood tests for early cancer detection. Researchers will explore whether superintelligence can identify abnormalities on scans before they become visible to the naked eye.
Ben Stanger, a cancer researcher at the University of Pennsylvania, and his team studied mice with mutations in a gene called Kras. These mutations produce proteins that can cause cancer. When tiny precancerous growths developed in the animals’ pancreases, the researchers gave them a drug that disables KRAS and related cancer-promoting proteins.
Nature reported that the treatment improved the mice’s survival. This was a separate animal experiment, not a treatment result from PRECEDE. Effective interception in humans has not been established, and Stanger cautioned that determining how best to use the technique in people could take years.
The mouse drug acts similarly to daraxonrasib, sold as Rasonque. Nature reported that the US Food and Drug Administration approved daraxonrasib in August, but that approval covers advanced cancer—not prevention.
Simeone said the PRECEDE consortium might test whether drugs such as daraxonrasib improve survival when given immediately after surgery to remove precancerous growths or early-stage tumours. That possible trial would help connect detection with treatment: finding an abnormality earlier creates an opportunity to act, but whether that intervention helps people live longer still needs to be tested.
3 min

The recreated mixture affected bacterial membranes, gene activity and communication. Researchers want to identify the active molecules, not recommend a homemade treatment.
3 min

Resources for the Future projects 1.83 gigatons less cumulative power-sector carbon dioxide through 2041 if the bill passes, though emissions grow with or without it. The estimate covers only the bill’s power-sector provisions.
3 min
Correction ·
House style applied: superintelligence (SI) for AI.
Correction ·
Corrected spelling and punctuation in the Armenian text.